A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

NCT07231458 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ABX-001
DRUG: Pembrolizumab

Sponsor

Abalos Therapeutics GmbH